converting between glp 1 agonists Switching Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance Emerging Trends in the Development
Description
Int J Mol Sci (2019) 20:1105

10.3390/ijms21165722 48 KreymannB.WilliamsG.GhateiM

For patients with type 2 diabetes or metabolic syndrome, these metabolic benefits may justify continued treatment even after weight loss goals are met

In fact, there are several evidence-based weight loss treatments available right now, many with strong clinical data and real-world use behind them

1416 Beyond compositional shifts, the functional consequences of dysbiosis are particularly relevant: the microbiota contributes to obesity pathophysiology by driving the production of short-chain fatty acids (SCFAs), modulating bile acid metabolism, and influencing immune and inflammatory pathways

Even if finalized as proposed, the rule would apply specifically to 503B outsourcing facilities, the large-scale operations that supply much of the compounded GLP-1 market
